Wall Street To Pharma: Strike A Deal On Drug Pricing And Resolve Uncertainty About Reform
Executive Summary
Pricing policies aimed at lowering Medicare Part B costs should be ‘relatively easy’ to accomplish but they wouldn’t be as effective in satisfying industry critics as reforms in Part D, securities analyst Geoffrey Porges says.
You may also be interested in...
Pharma Resisting Efforts To Send Drug Pricing Savings To US Budget ‘Black Hole’ – Pfizer’s Bourla
Biopharma draws a line in the sand on drug pricing reform and offers to come to the table, but given the fracturing support for Rx legislation within the Democratic caucus, industry may not have as much need to negotiate with Congress. More detail on industry’s latest proposals for lowering costs may come in the second half.
PhRMA’s ‘Better Way:’ Remember COVID Success, Tweak Part B, And Bash HR 3
Trade group’s new agenda offers few original solutions to tackle US drug costs, relying on old standbys and reminders of what medical innovation might be lost if industry is financially targeted by policy makers with a strong nod to drug manufacturers role the current pandemic.
Making The Case For A Legislative Deal On Drug Pricing
Drawing on 24 years as a legislator and another 16 years as a leading lobbyist for biopharma, Jim Greenwood sees an opportunity for industry to put drug pricing ‘behind us’ with a legislative compromise.